News Image

Why NYSE:PFE is a Top Pick for Dividend Investors.

By Mill Chart

Last update: Sep 21, 2023

Our stock screener has singled out PFIZER INC (NYSE:PFE) as a promising choice for dividend investors. NYSE:PFE not only scores well in profitability, solvency, and liquidity but also offers a decent dividend. We'll explore this further.

Assessing Dividend for NYSE:PFE

ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:PFE scores a 8 out of 10:

  • With a Yearly Dividend Yield of 4.80%, PFE is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 15.34, PFE pays a better dividend. On top of this PFE pays more dividend than 97.10% of the companies listed in the same industry.
  • PFE's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
  • PFE has been paying a dividend for at least 10 years, so it has a reliable track record.
  • PFE has not decreased their dividend for at least 10 years, which is a reliable track record.
  • Unpacking NYSE:PFE's Health Rating

    ChartMill employs a unique Health Rating system for all stocks. This rating, ranging from 0 to 10, is determined by analyzing various liquidity and solvency ratios. For NYSE:PFE, the assigned 5 for health provides valuable insights:

  • PFE has a Altman-Z score of 2.69. This is in the better half of the industry: PFE outperforms 73.43% of its industry peers.
  • PFE's Debt to FCF ratio of 6.13 is amongst the best of the industry. PFE outperforms 84.54% of its industry peers.
  • A Current Ratio of 2.12 indicates that PFE has no problem at all paying its short term obligations.
  • Understanding NYSE:PFE's Profitability

    ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NYSE:PFE scores a 8 out of 10:

  • Looking at the Return On Assets, with a value of 9.75%, PFE belongs to the top of the industry, outperforming 90.82% of the companies in the same industry.
  • With an excellent Return On Equity value of 21.68%, PFE belongs to the best of the industry, outperforming 91.79% of the companies in the same industry.
  • PFE has a better Return On Invested Capital (11.96%) than 89.86% of its industry peers.
  • The 3 year average ROIC (16.16%) for PFE is well above the current ROIC(11.96%). The reason for the recent decline needs to be investigated.
  • Looking at the Profit Margin, with a value of 27.55%, PFE belongs to the top of the industry, outperforming 94.69% of the companies in the same industry.
  • PFE has a better Operating Margin (31.21%) than 95.65% of its industry peers.
  • In the last couple of years the Operating Margin of PFE has grown nicely.
  • With a decent Gross Margin value of 68.78%, PFE is doing good in the industry, outperforming 73.43% of the companies in the same industry.
  • Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

    For an up to date full fundamental analysis you can check the fundamental report of PFE

    Disclaimer

    This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

    Back

    PFIZER INC

    NYSE:PFE (4/26/2024, 7:09:35 PM)

    After market: 25.45 +0.05 (+0.2%)

    25.4

    +0.14 (+0.55%)

    PFE News

    News Image3 hours ago - The Business JournalsPfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose

    Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.

    News Image11 hours ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

    The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

    News Image16 hours ago - The Motley Fool3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

    Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.

    News Image2 days ago - The Motley Fool3 Dividend Stocks to Buy and Hold for the Next Decade

    You'll get dividends and more with these great stocks.

    News Image2 days ago - InvestorPlace7 Dividend Stocks to Buy Now for Steady Returns in Any Market

    Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.

    News Image2 days ago - CNBCCramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly

    CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.

    News Image2 days ago - Market News VideoJune 7th Options Now Available For Pfizer (PFE)
    News Image3 days ago - The Motley FoolWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

    Put your money to work by investing in these three high-quality dividend stocks.

    News Image3 days ago - BloombergPfizer’s First Gene Therapy Gets Approval for Clotting Disorder

    Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.

    News Image3 days ago - CNBCFDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder

    The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B. 

    News Image3 days ago - Investor's Business DailyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy

    Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.

    News Image3 days ago - Pfizer Inc.U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
    PFE Links
    Follow us for more